The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Those included received 160-mg bimekizumab every 4 weeks and could enroll in the open-label extension study BE VITAL (NCT04009499) if they completed week 52 of BE OPTIMAL or week 16 of BE COMPLETE.

NICE is unable to make a recommendation about the use in the NHS of bimekizumab for treating moderate to severe hidradenitis suppurativa in adults. This is because UCB Pharma withdrew from the ...

BIMZELX ® (bimekizumab-bkzx) is now commercially available by prescription in the United States in a 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX The single ...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

The first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy targets in psoriasis – and performed better than Johnson & Johnson’s blockbuster rival Stelara.